Skip to main content
SpringerLink
Log in

Systemic Lupus Erythematosus in 2016

Gene expression profiling comes closer to the clinic

  • Year in Review
  • Published:

From Nature Reviews Rheumatology

View current issue Sign up to alerts

Gene expression profiling has been used for the first time to stratify patients with systemic lupus erythematosus (SLE) into potentially useful clinical groups, and also to further understand differences in the cell-specificity and nature of the interferon signature typical of SLE and other autoimmune diseases.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Figure 1: Insights into systemic lupus erythematosus (SLE) from gene expression profiling.

References

  1. de Jong, T. D. et al. Physiological evidence for diversification of IFNalpha- and IFNbeta-mediated response programs in different autoimmune diseases. Arthritis Res. Ther. 18, 49 (2016).

    Article  Google Scholar 

  2. Flint, S. M. et al. Leucocyte subset-specific type 1 interferon signatures in SLE and other immune-mediated diseases. RMD Open 2, e000183 (2016).

    Article  Google Scholar 

  3. Banchereau, R. et al. Personalized immunomonitoring uncovers molecular networks that stratify lupus patients. Cell 165, 1548–1550 (2016).

    Article  CAS  Google Scholar 

  4. van Baarsen, L. G. et al. Pharmacogenomics of interferon-beta therapy in multiple sclerosis: baseline IFN signature determines pharmacological differences between patients. PLoS One 3, e1927 (2008).

    Article  Google Scholar 

  5. Wampler Muskardin, T. et al. Increased pretreatment serum IFN-beta/alpha ratio predicts non-response to tumour necrosis factor alpha inhibition in rheumatoid arthritis. Ann. Rheum. Dis. 75, 1757–1762 (2016).

    Article  Google Scholar 

  6. Chaussabel, D. et al. A modular analysis framework for blood genomics studies: application to systemic lupus erythematosus. Immunity 29, 150–164 (2008).

    Article  CAS  Google Scholar 

  7. Coit, P. et al. Genome-wide DNA methylation study suggests epigenetic accessibility and transcriptional poising of interferon-regulated genes in naive CD4+ T cells from lupus patients. J. Autoimmun. 43, 78–84 (2013).

    Article  CAS  Google Scholar 

Download references

Acknowledgements

M.E.A.-R. is Head of the Management Entity of the Innovative Medicines Initiative Joint Undertaking project PRECISESADS under grant agreement n°115565, resources of which are composed of financial contributions from the European Union's 7th Framework Programme (FP7/2007-2013) and the European Federation of Pharmaceutical Industries and Associations in-kind contributions.

Author information

Authors and Affiliations

  1. GENYO (Centre for Genomics and Oncological Research), P. T. Ciencias de la Salud, Avenida de la Ilustración 114, Granada, 18016, Spain

    Guillermo Barturen

  2. GENYO (Centre for Genomics and Oncological Research), P. T. Ciencias de la Salud, Avenida de la Ilustración 114, 18016 Granada, Spain; and at the Unit for Chronic Inflammatory Diseases, Institute for Environmental Medicine, Karolinska Institutet, 171 67 Stockholm, Sweden.,

    Marta E. Alarcón-Riquelme

  3. and at the Unit for Chronic Inflammatory Diseases, Institute for Environmental Medicine, Karolinska Institutet, 171 67 Stockholm, Sweden.,

    Marta E. Alarcón-Riquelme

Authors
  1. Guillermo Barturen
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Marta E. Alarcón-Riquelme
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Marta E. Alarcón-Riquelme.

Ethics declarations

Competing interests

G.B. receives support from Sanofi/Genzyme in the context of a grant from the Innovative Medicines Initiative. M.E.A.-R. declares that she is in receipt of a grant from the Innovative Medicines Initiative that includes in-kind contributions by Bayer, Eli-Lilly, UCB Pharma, IRIS Servier and an in-cash contribution from Sanofi/Genzyme.

PowerPoint slides

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Barturen, G., Alarcón-Riquelme, M. Gene expression profiling comes closer to the clinic. Nat Rev Rheumatol 13, 69–70 (2017). https://doi.org/10.1038/nrrheum.2016.211

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrrheum.2016.211

  • Springer Nature Limited

This article is cited by

Search

Navigation